Is it finally time for small-cap and mid-cap stocks to overtake large caps’ long-time leadership?
Here are the year-to-date returns for major U.S. index ETFs:
Stocks driving that large-cap index performance include names you’ve become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
What small-cap premium?
In recent times, large-cap stocks have been dominant despite an investing thesis called the small-cap premium.
The small-cap premium refers to the historical tendency of small-cap stocks to outperform their larger counterparts over time. This phenomenon is attributed to the higher risk associated with smaller companies, leading to increased potential for growth. Investors typically expect a higher return from a smaller stock, in exchange for the additional risk of holding these less-established or less liquid companies.
However, large caps have thrived due to factors including higher borrowing costs, which are easier for large companies to absorb; the quest for income amid economic uncertainties; and the leadership of big techs, driven by AI in 2023.
Year-to-date, technology stocks in the Technology Select Sector SPDR Fund NYSEARCA: XLK and the Communication Services Select Sector SPDR Fund NYSEARCA: XLC have been the big leaders, although eight of the S&P sectors are up this year.
But is it time for a changing of the guard? Smaller stocks are trading at more attractive valuations, relative to larger stocks. That could draw investors looking for equities they can nab at less frothy levels.
Small caps' favorable P/Es
A Bank of America November research report noted that the small-cap Russell 2000 forward price-to-earnings ratio fell to a 14-month low. It’s currently at 12.3 times forward earnings, down from 12.9 times.
Meanwhile, the Russell MidCap P/E fell to 14.6 times forward earnings from 15.1 times. That’s now below the historical average.
Large-cap valuations are also falling, as the Russell 1000 P/E fell to 17.3 times forward earnings, down from 17.9 times. However, small caps remain the cheapest size segment, trading at a 19% discount vs. historical levels, while mid-caps are also now cheap, trading at a 4% discount versus historical levels.
When scouting for small-cap stocks, investors often have to research stocks that aren’t household names.
Optimism about small biotechs
Analysts are bullish about several small-cap stocks in the healthcare sector.
For example, Avid Bioservices Inc. NASDAQ: CDMO, Vir Biotechnology Inc. NASDAQ: VIR and Arcus Biosciences Inc. NASDAQ: RCUS are all expected to triple in price in the next 12 to 18 months, according to Wall Street forecasts.
All of those small-cap biotech stocks are trading well below prior highs and there’s nothing bullish about any of those charts. In addition, biotech is a notoriously risky industry, with that risk amplified when you’re talking about small caps.
Other factors are working in small caps’ favor.
Of the SPDR Portfolio S&P 600 Small Cap ETF NYSEARCA: SPSM components that have reported third-quarter results, more than three quarters beat analyst estimates.
Lower rates can boost small caps
In addition, if interest rates decline or remain stagnant, that’s a positive for small caps, as their cost of capital comes down, which bodes well for their growth.
Finally, presidential election years frequently result in solid gains for small-cap stocks.
In what’s possibly a preview of things to come, small caps outperformed their larger peers in the Thanksgiving-shortened session on November 24.
The SPSM ETF advanced 0.53% in the session, while the SPY ETF was up just fractionally.
Now, one holiday session doesn’t signal a trend, but the elements could be in place for smaller stocks to rotate into leadership.
U.S. small stocks haven’t outperformed larger stocks since 2016, but asset classes eventually take leadership, even after years of underperformance.
Before you consider Tesla, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tesla wasn't on the list.
While Tesla currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.